ClinicalTrials.gg
CompletedNCT01763918RUTHERFORD-2Updated Jun 17, 2019Results posted

Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2

A Phase 3 interventional study of Evolocumab and Placebo in Hyperlipidemia, sponsored by Amgen. Completed at 39 sites in 14 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-06-17.

Primary conditionHypercholesterolemiaRegistry: HyperlipidemiasReclassifiedWhy we changed it
Registry
Hyperlipidemias — the first condition term the registry derived for this study.
ClinicalTrials.gg
Hypercholesterolemia
Why
  1. The study's title name Hypercholesterolemia, a narrower term within Hyperlipidemias.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
331
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing evolocumab in Hypercholesterolemia — 1 open to participants now, 1 under way, none of them phase 3. evolocumab · Hypercholesterolemia.

Enrollment
16th of 36
331 · median 308
Started
2013
with 10 others
Phase 3
22 of 36
none open now
Registered
9th of 36
by date
Lead sponsor
30 of 36
Amgen

Among the 36 studies testing evolocumab in Hypercholesterolemia, this one is the 16th largest by enrollment, is one of 11 that started in 2013, is one of 22 in phase 3, and was the 9th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

1 of the 36 studies testing evolocumab in Hypercholesterolemia is open now. Recruiting first, the newest first:

About evolocumab

evolocumab: first FDA approval 2015 (REPATHA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing evolocumab in Hypercholesterolemia, or all of them as a file.
02

Study summary

The primary objective was to evaluate the effect of 12 weeks of evolocumab subcutaneously once every 2 weeks (Q2W) and once monthly (QM), compared with placebo, on percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in adults with heterozygous familial hypercholesterolemia (HeFH).

03

Conditions studied

  • Hyperlipidemia

Browse trials for

Keywords

  • High cholesterol, Treatment for high cholesterol, Lowering cholesterol, Lowering high cholesterol, Hypercholesterolemia
04

In context

Hypercholesterolemia Reclassified

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

This study's enrollment of 331 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.

Browse Hypercholesterolemia studies →

Lead sponsor

Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.

Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.

Compared within Hypercholesterolemia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hyperlipidemias. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female ≥ 18 to ≤ 80 years of age
  • Diagnosis of heterozygous familial hypercholesterolemia
  • On a stable dose of an approved statin and lipid regulating medication
  • Fasting LDL-C ≥ 100 mg/dL (2.6 mmol/L)
  • Fasting triglycerides ≤ 400 mg/dL (4.5 mmol/L)

Exclusion criteria

Exclusion Criteria:

  • Homozygous familial hypercholesterolemia
  • LDL or plasma apheresis
  • (NYHA) III or IV heart failure
  • Uncontrolled cardiac arrhythmia
  • Uncontrolled hypertension
  • Type 1 diabetes, poorly controlled type 2 diabetes
  • Uncontrolled hypothyroidism or hyperthyroidism
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
331 participants (actual)

Study arms

  • Placebo comparator
    Placebo Q2W

    Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for up to 12 weeks.

    Drug: Placebo

  • Placebo comparator
    Placebo QM

    Participants received placebo subcutaneous injection once every month (QM) for up to 12 weeks.

    Drug: Placebo

  • Experimental
    Evolocumab Q2W

    Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.

    Biological: Evolocumab

  • Experimental
    Evolocumab QM

    Participants received 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.

    Biological: Evolocumab

Interventions

  • BiologicalEvolocumab

    Administered by subcutaneous injection

    Also known as: AMG 145, Repatha

  • DrugPlacebo

    Administered by subcutaneous injection

07

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in LDL-C at Week 12

    Time frame: Baseline and Week 12

  2. Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12

    Time frame: Baseline and Weeks 10 and 12

Secondary outcomes

  1. Change From Baseline in LDL-C at the Mean of Weeks 10 and 12

    Time frame: Baseline and Weeks 10 and 12

  2. Change From Baseline in LDL-C at Week 12

    Time frame: Baseline and Week 12

  3. Percentage of Participants With Mean LDL-C at Weeks 10 and 12 of Less Than 70 mg/dL (1.8 mmol/L)

    Time frame: Weeks 10 and 12

  4. Percentage of Participants With LDL-C < 70 mg/dL (1.8 mmol/L) at Week 12

    Time frame: Week 12

  5. Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) at the Mean of Weeks 10 and 12

    Time frame: Baseline and Weeks 10 and 12

  6. Percent Change From Baseline in Non-HDL-C at Week 12

    Time frame: Baseline and Week 12

  7. Percent Change From Baseline in Apolipoprotein B at the Mean of Weeks 10 and 12

    Time frame: Baseline and Weeks 10 and 12

  8. Percent Change From Baseline in Apolipoprotein B at Week 12

    Time frame: Baseline and Week 12

  9. Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at the Mean of Weeks 10 and 12

    Time frame: Baseline and Weeks 10 and 12

  10. Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at Week 12

    Time frame: Baseline and Week 12

  11. Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at the Mean of Weeks 10 and 12

    Time frame: Baseline and Weeks 10 and 12

  12. Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 12

    Time frame: Baseline and Week 12

  13. Percent Change From Baseline in Lipoprotein (a) at the Mean of Weeks 10 and 12

    Time frame: Baseline and Weeks 10 and 12

  14. Percent Change From Baseline in Lipoprotein (a) at Week 12

    Time frame: Baseline and Week 12

  15. Percent Change From Baseline in Triglycerides at the Mean of Weeks 10 and 12

    Time frame: Baseline and Weeks 10 and 12

  16. Percent Change From Baseline in Triglycerides at Week 12

    Time frame: Baseline and Week 12

  17. Percent Change From Baseline in HDL-C at the Mean of Weeks 10 and 12

    Time frame: Baseline and Weeks 10 and 12

  18. Percent Change From Baseline in HDL-C at Week 12

    Time frame: Baseline and Week 12

  19. Percent Change From Baseline in Very Low-Density Lipoprotein Cholesterol (VLDL-C) at the Mean of Weeks 10 and 12

    Time frame: Baseline and Weeks 10 and 12

  20. Percent Change From Baseline in VLDL-C at Week 12

    Time frame: Baseline and Week 12

08

Results

Posted Dec 22, 2015

Participant flow

Men and women 18 to 80 years old with a diagnosis of heterozygous familial hypercholesterolemia (HeFH) on stable doses of an approved statin with fasting low-density lipoprotein cholesterol (LDL-C) ≥ 100 mg/dL were eligible for this study. The first participant enrolled on 07 February 2013 and the last participant enrolled 03 September 2013.

Participant flow — Overall Study
MilestonePlacebo Q2WPlacebo QMEvolocumab Q2WEvolocumab QM
Started5555111110
Received treatment5455110110
Completed4954101108
Not completed61102
Withdrew: Withdrawal by subject2112
Withdrew: Sponsor decision4090

Outcome measures

PrimaryPercent Change From Baseline in LDL-C at Week 12
Time frame:
Baseline and Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in LDL-C at Week 12
percent changePlacebo Q2WPlacebo QMEvolocumab Q2WEvolocumab QM
Percent Change From Baseline in LDL-C at Week 12-2.02 ± 2.495.53 ± 3.25-61.25 ± 1.77-55.74 ± 2.25
Statistical analysis
  • Placebo Q2W vs Evolocumab Q2W · Repeated measures linear effects model · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -59.23 · 95% CI -65.11 to -53.35The model includes treatment group, baseline LDL-C and ezetimibe use, scheduled visit, and the interaction of treatment with scheduled visit.
  • Placebo QM vs Evolocumab QM · Repeated measures linear effects model · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -61.27 · 95% CI -69.00 to -53.55The model includes treatment group, baseline LDL-C and ezetimibe use, scheduled visit, and the interaction of treatment with scheduled visit.
PrimaryPercent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12
Time frame:
Baseline and Weeks 10 and 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12
percent changePlacebo Q2WPlacebo QMEvolocumab Q2WEvolocumab QM
Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12-1.08 ± 2.412.30 ± 2.41-61.23 ± 1.71-63.25 ± 1.70
Statistical analysis
  • Placebo Q2W vs Evolocumab Q2W · Repeated measures linear effects model · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -60.15 · 95% CI -65.83 to -54.46The model includes treatment group, baseline LDL-C and ezetimibe use, scheduled visit, and the interaction of treatment with scheduled visit.
  • Placebo QM vs Evolocumab QM · Repeated measures linear effects model · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -65.55 · 95% CI -71.27 to -59.83The model includes treatment group, baseline LDL-C and ezetimibe use, scheduled visit, and the interaction of treatment with scheduled visit.
SecondaryChange From Baseline in LDL-C at the Mean of Weeks 10 and 12
Time frame:
Baseline and Weeks 10 and 12
Reported as:
Least squares mean · mg/dL
Change From Baseline in LDL-C at the Mean of Weeks 10 and 12
mg/dLPlacebo Q2WPlacebo QMEvolocumab Q2WEvolocumab QM
Change From Baseline in LDL-C at the Mean of Weeks 10 and 12-6.5 ± 4.2-1.3 ± 4.1-101.7 ± 3.0-98.8 ± 2.9
Statistical analysis
  • Placebo Q2W vs Evolocumab Q2W · Repeated measures linear effects model · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -95.2 · 95% CI -105.1 to -85.2The model includes treatment group, baseline LDL-C and ezetimibe use, scheduled visit, and the interaction of treatment with scheduled visit.
  • Placebo QM vs Evolocumab QM · Repeated measures linear effects model · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -97.4 · 95% CI -107.1 to -87.7The model includes treatment group, baseline LDL-C and ezetimibe use, scheduled visit, and the interaction of treatment with scheduled visit.
SecondaryChange From Baseline in LDL-C at Week 12
Time frame:
Baseline and Week 12
Reported as:
Least squares mean · mg/dL
Change From Baseline in LDL-C at Week 12
mg/dLPlacebo Q2WPlacebo QMEvolocumab Q2WEvolocumab QM
Change From Baseline in LDL-C at Week 12-8.5 ± 4.24.1 ± 5.2-101.3 ± 3.0-87.2 ± 3.6
Statistical analysis
  • Placebo Q2W vs Evolocumab Q2W · Repeated measures linear effects model · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -92.9 · 95% CI -102.9 to -82.8The model includes treatment group, baseline LDL-C and ezetimibe use, scheduled visit, and the interaction of treatment with scheduled visit.
  • Placebo QM vs Evolocumab QM · Repeated measures linear effects model · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -91.3 · 95% CI -103.8 to -78.9The model includes treatment group, baseline LDL-C and ezetimibe use, scheduled visit, and the interaction of treatment with scheduled visit.
SecondaryPercentage of Participants With Mean LDL-C at Weeks 10 and 12 of Less Than 70 mg/dL (1.8 mmol/L)
Time frame:
Weeks 10 and 12
Reported as:
Number · percentage of participants
Percentage of Participants With Mean LDL-C at Weeks 10 and 12 of Less Than 70 mg/dL (1.8 mmol/L)
percentage of participantsPlacebo Q2WPlacebo QMEvolocumab Q2WEvolocumab QM
Percentage of Participants With Mean LDL-C at Weeks 10 and 12 of Less Than 70 mg/dL (1.8 mmol/L)1.9 (0.3 to 9.9)1.9 (0.3 to 9.8)67.0 (57.7 to 75.1)80.4 (71.9 to 86.8)
Statistical analysis
  • Placebo Q2W vs Evolocumab Q2W · Cochran-Mantel-Haenszel · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Treatment difference: 65.1 · 95% CI 52.8 to 73.4Cochran-Mantel Haenszel test stratified by baseline LDL-C and ezetimibe use.
  • Placebo QM vs Evolocumab QM · Cochran-Mantel-Haenszel · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Treatment difference: 78.5 · 95% CI 66.9 to 85.1Cochran-Mantel Haenszel test stratified by baseline LDL-C and ezetimibe use.
SecondaryPercentage of Participants With LDL-C < 70 mg/dL (1.8 mmol/L) at Week 12
Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With LDL-C < 70 mg/dL (1.8 mmol/L) at Week 12
percentage of participantsPlacebo Q2WPlacebo QMEvolocumab Q2WEvolocumab QM
Percentage of Participants With LDL-C < 70 mg/dL (1.8 mmol/L) at Week 122.0 (0.3 to 10.3)2.2 (0.4 to 11.3)68.3 (58.8 to 76.4)63.1 (53.5 to 71.8)
Statistical analysis
  • Placebo Q2W vs Evolocumab Q2W · Cochran-Mantel-Haenszel · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Treatment difference: 66.3 · 95% CI 53.7 to 74.6Cochran-Mantel Haenszel test stratified by baseline LDL-C and ezetimibe use
  • Placebo QM vs Evolocumab QM · Cochran-Mantel-Haenszel · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Treatment difference: 60.9 · 95% CI 47.6 to 69.8Cochran-Mantel Haenszel test stratified by baseline LDL-C and ezetimibe use.
SecondaryPercent Change From Baseline in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) at the Mean of Weeks 10 and 12
Time frame:
Baseline and Weeks 10 and 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) at the Mean of Weeks 10 and 12
percent changePlacebo Q2WPlacebo QMEvolocumab Q2WEvolocumab QM
Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) at the Mean of Weeks 10 and 120.21 ± 2.292.72 ± 2.21-55.79 ± 1.63-57.28 ± 1.56
Statistical analysis
  • Placebo Q2W vs Evolocumab Q2W · Repeated measures linear effects model · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -56.00 · 95% CI -61.41 to -50.59The model includes treatment group, baseline LDL-C and ezetimibe use, scheduled visit, and the interaction of treatment with scheduled visit.
  • Placebo QM vs Evolocumab QM · Repeated measures linear effects model · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -60.01 · 95% CI -65.24 to -54.77The model includes treatment group, baseline LDL-C and ezetimibe use, scheduled visit, and the interaction of treatment with scheduled visit.
SecondaryPercent Change From Baseline in Non-HDL-C at Week 12
Time frame:
Baseline and Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Non-HDL-C at Week 12
percent changePlacebo Q2WPlacebo QMEvolocumab Q2WEvolocumab QM
Percent Change From Baseline in Non-HDL-C at Week 12-1.39 ± 2.405.29 ± 2.94-56.19 ± 1.71-49.67 ± 2.04
Statistical analysis
  • Placebo Q2W vs Evolocumab Q2W · Repeated measures linear effects model · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -54.79 · 95% CI -60.47 to -49.12The model includes treatment group, baseline LDL-C and ezetimibe use, scheduled visit, and the interaction of treatment with scheduled visit.
  • Placebo QM vs Evolocumab QM · Repeated measures linear effects model · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -54.95 · 95% CI -61.95 to -47.96The model includes treatment group, baseline LDL-C and ezetimibe use, scheduled visit, and the interaction of treatment with scheduled visit.
SecondaryPercent Change From Baseline in Apolipoprotein B at the Mean of Weeks 10 and 12
Time frame:
Baseline and Weeks 10 and 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apolipoprotein B at the Mean of Weeks 10 and 12
percent changePlacebo Q2WPlacebo QMEvolocumab Q2WEvolocumab QM
Percent Change From Baseline in Apolipoprotein B at the Mean of Weeks 10 and 12-0.19 ± 2.102.21 ± 1.97-49.58 ± 1.48-52.76 ± 1.36
Statistical analysis
  • Placebo Q2W vs Evolocumab Q2W · Repeated measures linear effects model · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -49.39 · 95% CI -54.32 to -44.46The model includes treatment group, baseline LDL-C and ezetimibe use, scheduled visit, and the interaction of treatment with scheduled visit.
  • Placebo QM vs Evolocumab QM · Repeated measures linear effects model · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -54.98 · 95% CI -59.58 to -50.38The model includes treatment group, baseline LDL-C and ezetimibe use, scheduled visit, and the interaction of treatment with scheduled visit.
SecondaryPercent Change From Baseline in Apolipoprotein B at Week 12
Time frame:
Baseline and Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apolipoprotein B at Week 12
percent changePlacebo Q2WPlacebo QMEvolocumab Q2WEvolocumab QM
Percent Change From Baseline in Apolipoprotein B at Week 12-0.67 ± 2.324.60 ± 2.70-49.75 ± 1.63-44.81 ± 1.80
Statistical analysis
  • Placebo Q2W vs Evolocumab Q2W · Repeated measures linear effects model · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -49.09 · 95% CI -54.55 to -43.63The model includes treatment group, baseline LDL-C and ezetimibe use, scheduled visit, and the interaction of treatment with scheduled visit.
  • Placebo QM vs Evolocumab QM · Repeated measures linear effects model · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -49.41 · 95% CI -55.73 to -43.10The model includes treatment group, baseline LDL-C and ezetimibe use, scheduled visit, and the interaction of treatment with scheduled visit.
SecondaryPercent Change From Baseline in the Total Cholesterol/HDL-C Ratio at the Mean of Weeks 10 and 12
Time frame:
Baseline and Weeks 10 and 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at the Mean of Weeks 10 and 12
percent changePlacebo Q2WPlacebo QMEvolocumab Q2WEvolocumab QM
Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at the Mean of Weeks 10 and 120.86 ± 2.054.14 ± 2.13-45.74 ± 1.45-45.02 ± 1.50
Statistical analysis
  • Placebo Q2W vs Evolocumab Q2W · Repeated measures linear effects model · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -46.59 · 95% CI -51.43 to -41.76The model includes treatment group, baseline LDL-C and ezetimibe use, scheduled visit, and the interaction of treatment with scheduled visit.
  • Placebo QM vs Evolocumab QM · Repeated measures linear effects model · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -49.16 · 95% CI -54.21 to -44.11The model includes treatment group, baseline LDL-C and ezetimibe use, scheduled visit, and the interaction of treatment with scheduled visit.
SecondaryPercent Change From Baseline in the Total Cholesterol/HDL-C Ratio at Week 12
Time frame:
Baseline and Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at Week 12
percent changePlacebo Q2WPlacebo QMEvolocumab Q2WEvolocumab QM
Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at Week 120.12 ± 2.197.11 ± 3.13-45.95 ± 1.56-38.32 ± 2.15
Statistical analysis
  • Placebo Q2W vs Evolocumab Q2W · Repeated measures linear effects model · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -46.08 · 95% CI -51.27 to -40.88The model includes treatment group, baseline LDL-C and ezetimibe use, scheduled visit, and the interaction of treatment with scheduled visit.
  • Placebo QM vs Evolocumab QM · Repeated measures linear effects model · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -45.42 · 95% CI -52.86 to -37.98The model includes treatment group, baseline LDL-C and ezetimibe use, scheduled visit, and the interaction of treatment with scheduled visit.
SecondaryPercent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at the Mean of Weeks 10 and 12
Time frame:
Baseline and Weeks 10 and 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at the Mean of Weeks 10 and 12
percent changePlacebo Q2WPlacebo QMEvolocumab Q2WEvolocumab QM
Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at the Mean of Weeks 10 and 120.78 ± 2.211.65 ± 2.35-52.39 ± 1.56-53.91 ± 1.60
Statistical analysis
  • Placebo Q2W vs Evolocumab Q2W · Repeated measures linear effects model · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -53.17 · 95% CI -58.35 to -47.99The model includes treatment group, baseline LDL-C and ezetimibe use, scheduled visit, and the interaction of treatment with scheduled visit.
  • Placebo QM vs Evolocumab QM · Repeated measures linear effects model · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -55.56 · 95% CI -61.08 to -50.05The model includes treatment group, baseline LDL-C and ezetimibe use, scheduled visit, and the interaction of treatment with scheduled visit.
SecondaryPercent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 12
Time frame:
Baseline and Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 12
percent changePlacebo Q2WPlacebo QMEvolocumab Q2WEvolocumab QM
Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 121.54 ± 2.494.23 ± 3.66-52.74 ± 1.75-45.31 ± 2.42
Statistical analysis
  • Placebo Q2W vs Evolocumab Q2W · Repeated measures linear effects model · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -54.28 · 95% CI -60.16 to -48.41The model includes treatment group, baseline LDL-C and ezetimibe use, scheduled visit, and the interaction of treatment with scheduled visit.
  • Placebo QM vs Evolocumab QM · Repeated measures linear effects model · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -49.55 · 95% CI -58.14 to -40.96The model includes treatment group, baseline LDL-C and ezetimibe use, scheduled visit, and the interaction of treatment with scheduled visit.
SecondaryPercent Change From Baseline in Lipoprotein (a) at the Mean of Weeks 10 and 12
Time frame:
Baseline and Weeks 10 and 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Lipoprotein (a) at the Mean of Weeks 10 and 12
percent changePlacebo Q2WPlacebo QMEvolocumab Q2WEvolocumab QM
Percent Change From Baseline in Lipoprotein (a) at the Mean of Weeks 10 and 127.34 ± 2.975.35 ± 2.95-24.03 ± 2.09-25.65 ± 2.07
Statistical analysis
  • Placebo Q2W vs Evolocumab Q2W · Repeated measures linear effects model · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -31.37 · 95% CI -38.33 to -24.41The model includes treatment group, baseline LDL-C and ezetimibe use, scheduled visit, and the interaction of treatment with scheduled visit.
  • Placebo QM vs Evolocumab QM · Repeated measures linear effects model · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -31.00 · 95% CI -37.91 to -24.09The model includes treatment group, baseline LDL-C and ezetimibe use, scheduled visit, and the interaction of treatment with scheduled visit.
SecondaryPercent Change From Baseline in Lipoprotein (a) at Week 12
Time frame:
Baseline and Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Lipoprotein (a) at Week 12
percent changePlacebo Q2WPlacebo QMEvolocumab Q2WEvolocumab QM
Percent Change From Baseline in Lipoprotein (a) at Week 128.68 ± 3.276.69 ± 3.16-22.89 ± 2.31-21.55 ± 2.17
Statistical analysis
  • Placebo Q2W vs Evolocumab Q2W · Repeated measures linear effects model · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -31.57 · 95% CI -39.28 to -23.87The model includes treatment group, baseline LDL-C and ezetimibe use, scheduled visit, and the interaction of treatment with scheduled visit.
  • Placebo QM vs Evolocumab QM · Repeated measures linear effects model · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -28.24 · 95% CI -35.61 to -20.88The model includes treatment group, baseline LDL-C and ezetimibe use, scheduled visit, and the interaction of treatment with scheduled visit.
SecondaryPercent Change From Baseline in Triglycerides at the Mean of Weeks 10 and 12
Time frame:
Baseline and Weeks 10 and 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Triglycerides at the Mean of Weeks 10 and 12
percent changePlacebo Q2WPlacebo QMEvolocumab Q2WEvolocumab QM
Percent Change From Baseline in Triglycerides at the Mean of Weeks 10 and 129.09 ± 3.027.49 ± 3.26-13.27 ± 2.14-9.25 ± 2.27
Statistical analysis
  • Placebo Q2W vs Evolocumab Q2W · Repeated measures linear effects model · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -22.36 · 95% CI -29.48 to -15.24The model includes treatment group, baseline LDL-C and ezetimibe use, scheduled visit, and the interaction of treatment with scheduled visit.
  • Placebo QM vs Evolocumab QM · Repeated measures linear effects model · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -16.74 · 95% CI -24.43 to -9.05The model includes treatment group, baseline LDL-C and ezetimibe use, scheduled visit, and the interaction of treatment with scheduled visit.
SecondaryPercent Change From Baseline in Triglycerides at Week 12
Time frame:
Baseline and Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Triglycerides at Week 12
percent changePlacebo Q2WPlacebo QMEvolocumab Q2WEvolocumab QM
Percent Change From Baseline in Triglycerides at Week 123.50 ± 3.516.43 ± 4.15-16.09 ± 2.49-5.13 ± 2.84
Statistical analysis
  • Placebo Q2W vs Evolocumab Q2W · Repeated measures linear effects model · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -19.59 · 95% CI -27.92 to -11.26The model includes treatment group, baseline LDL-C and ezetimibe use, scheduled visit, and the interaction of treatment with scheduled visit.
  • Placebo QM vs Evolocumab QM · Repeated measures linear effects model · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -11.56 · 95% CI -21.38 to -1.74The model includes treatment group, baseline LDL-C and ezetimibe use, scheduled visit, and the interaction of treatment with scheduled visit.
SecondaryPercent Change From Baseline in HDL-C at the Mean of Weeks 10 and 12
Time frame:
Baseline and Weeks 10 and 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in HDL-C at the Mean of Weeks 10 and 12
percent changePlacebo Q2WPlacebo QMEvolocumab Q2WEvolocumab QM
Percent Change From Baseline in HDL-C at the Mean of Weeks 10 and 12-0.45 ± 1.70-2.86 ± 1.847.93 ± 1.206.62 ± 1.29
Statistical analysis
  • Placebo Q2W vs Evolocumab Q2W · Repeated measures linear effects model · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: 8.38 · 95% CI 4.36 to 12.40The model includes treatment group, baseline LDL-C and ezetimibe use, scheduled visit, and the interaction of treatment with scheduled visit.
  • Placebo QM vs Evolocumab QM · Repeated measures linear effects model · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: 9.48 · 95% CI 5.10 to 13.85The model includes treatment group, baseline LDL-C and ezetimibe use, scheduled visit, and the interaction of treatment with scheduled visit.
SecondaryPercent Change From Baseline in HDL-C at Week 12
Time frame:
Baseline and Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in HDL-C at Week 12
percent changePlacebo Q2WPlacebo QMEvolocumab Q2WEvolocumab QM
Percent Change From Baseline in HDL-C at Week 12-1.15 ± 1.91-3.73 ± 2.358.05 ± 1.355.35 ± 1.62
Statistical analysis
  • Placebo Q2W vs Evolocumab Q2W · Repeated measures linear effects model · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: 9.20 · 95% CI 4.66 to 13.74The model includes treatment group, baseline LDL-C and ezetimibe use, scheduled visit, and the interaction of treatment with scheduled visit.
  • Placebo QM vs Evolocumab QM · Repeated measures linear effects model · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: 9.07 · 95% CI 3.48 to 1466The model includes treatment group, baseline LDL-C and ezetimibe use, scheduled visit, and the interaction of treatment with scheduled visit.
SecondaryPercent Change From Baseline in Very Low-Density Lipoprotein Cholesterol (VLDL-C) at the Mean of Weeks 10 and 12
Time frame:
Baseline and Weeks 10 and 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Very Low-Density Lipoprotein Cholesterol (VLDL-C) at the Mean of Weeks 10 and 12
percent changePlacebo Q2WPlacebo QMEvolocumab Q2WEvolocumab QM
Percent Change From Baseline in Very Low-Density Lipoprotein Cholesterol (VLDL-C) at the Mean of Weeks 10 and 128.66 ± 2.906.34 ± 3.27-13.97 ± 2.06-9.20 ± 2.27
Statistical analysis
  • Placebo Q2W vs Evolocumab Q2W · Repeated measures linear effects model · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -22.63 · 95% CI -29.46 to -15.81The model includes treatment group, baseline LDL-C and ezetimibe use, scheduled visit, and the interaction of treatment with scheduled visit.
  • Placebo QM vs Evolocumab QM · Repeated measures linear effects model · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -15.54 · 95% CI -23.25 to -7.84The model includes treatment group, baseline LDL-C and ezetimibe use, scheduled visit, and the interaction of treatment with scheduled visit.
SecondaryPercent Change From Baseline in VLDL-C at Week 12
Time frame:
Baseline and Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in VLDL-C at Week 12
percent changePlacebo Q2WPlacebo QMEvolocumab Q2WEvolocumab QM
Percent Change From Baseline in VLDL-C at Week 123.73 ± 3.504.10 ± 4.17-17.25 ± 2.48-5.06 ± 2.84
Statistical analysis
  • Placebo Q2W vs Evolocumab Q2W · Repeated measures linear effects model · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -20.97 · 95% CI -29.29 to -12.66The model includes treatment group, baseline LDL-C and ezetimibe use, scheduled visit, and the interaction of treatment with scheduled visit.
  • Placebo QM vs Evolocumab QM · Repeated measures linear effects model · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -9.17 · 95% CI -19.01 to 0.68The model includes treatment group, baseline LDL-C and ezetimibe use, scheduled visit, and the interaction of treatment with scheduled visit.

Adverse events

Collected over From the first dose of blinded investigational product until the end of the study (up to 14 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo Q2W—2/54 (3.7%)5/54 (9.3%)
Placebo QM—3/55 (5.5%)10/55 (18.2%)
Evolocumab Q2W—3/110 (2.7%)17/110 (15.5%)
Evolocumab QM—4/110 (3.6%)24/110 (21.8%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventPlacebo Q2WPlacebo QMEvolocumab Q2WEvolocumab QM
Coronary artery diseaseCardiac disorders1/540/550/1100/110
Inguinal herniaGastrointestinal disorders1/540/550/1100/110
Blood creatine phosphokinase increasedInvestigations0/541/550/1100/110
DepressionPsychiatric disorders0/541/550/1100/110
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/541/550/1100/110
Acute myocardial infarctionCardiac disorders0/540/551/1100/110
Angina pectorisCardiac disorders0/540/551/1101/110
Pancreatitis acuteGastrointestinal disorders0/540/550/1101/110
Colonoscopy abnormalInvestigations0/540/550/1101/110
Endoscopy gastrointestinal abnormalInvestigations0/540/550/1101/110
Most frequent other events
Most frequent other events
EventPlacebo Q2WPlacebo QMEvolocumab Q2WEvolocumab QM
NasopharyngitisInfections and infestations2/543/558/11011/110
ArthralgiaMusculoskeletal and connective tissue disorders1/541/557/1101/110
Back painMusculoskeletal and connective tissue disorders0/541/552/1106/110
DizzinessNervous system disorders1/543/550/1104/110
HeadacheNervous system disorders1/543/554/1105/110

Baseline characteristics

Age, Continuous
Age, Continuous(years)Placebo Q2WPlacebo QMEvolocumab Q2WEvolocumab QMTotal
Mean51.1 ± 14.146.8 ± 12.152.3 ± 12.651.9 ± 12.051.1 ± 12.7
Sex: Female, Male
Sex: Female, Male(Participants)Placebo Q2WPlacebo QMEvolocumab Q2WEvolocumab QMTotal
Female25244546140
Male30316664191
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Placebo Q2WPlacebo QMEvolocumab Q2WEvolocumab QMTotal
American Indian or Alaska Native00000
Asian134816
Black or African American10113
Native Hawaiian or Other Pacific Islander00000
White514910098298
Other236314
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Placebo Q2WPlacebo QMEvolocumab Q2WEvolocumab QMTotal
Hispanic or Latino10012
Not Hispanic or Latino5455111109329
Stratification Factor: Low-Density Lipoprotein Cholesterol (LDL-C) Level
Stratification Factor: Low-Density Lipoprotein Cholesterol (LDL-C) Level(participants)Placebo Q2WPlacebo QMEvolocumab Q2WEvolocumab QMTotal
< 160 mg/dL35357070210
≥ 160 mg/dL20204140121
Baseline Ezetimibe Use
Baseline Ezetimibe Use(participants)Placebo Q2WPlacebo QMEvolocumab Q2WEvolocumab QMTotal
No22214343129
Yes33346867202
LDL-C Concentration
LDL-C Concentration(mg/dL)Placebo Q2WPlacebo QMEvolocumab Q2WEvolocumab QMTotal
Mean151.1 ± 36.5151.5 ± 42.5161.4 ± 51.0153.6 ± 43.3155.5 ± 44.9
Non-High-Density Lipoprotein Cholesterol (non-HDL-C) Concentration
Non-High-Density Lipoprotein Cholesterol (non-HDL-C) Concentration(mg/dL)Placebo Q2WPlacebo QMEvolocumab Q2WEvolocumab QMTotal
Mean175.4 ± 43.9175.4 ± 45.9187.4 ± 56.7178.5 ± 45.8180.4 ± 49.5

7 further baseline measures are reported on the registry.

09

Study locations

39 sites
  • Research Site
    Scottsdale, Arizona 85258, United States
  • Research Site
    Cincinnati, Ohio 45227, United States
  • Research Site
    Camperdown, New South Wales 2015, Australia
  • Research Site
    Perth, Western Australia 6000, Australia
  • Research Site
    Vancouver, British Columbia V6Z 1Y6, Canada
  • Research Site
    London, Ontario N6A 5K8, Canada
  • Research Site
    Chicoutimi, Quebec G7H 7K9, Canada
  • Research Site
    Montreal, Quebec H2W 1R7, Canada
  • Research Site
    Montreal, Quebec H3A 1A1, Canada
  • Research Site
    Bron, 69677, France
  • Research Site
    Nantes Cedex 1, 44093, France
  • Research Site
    Paris Cedex 13, 75651, France
  • Research Site
    Köln, 50937, Germany
  • Research Site
    New Territories, Hong Kong
  • Research Site
    Amersfoort, 3813 TZ, Netherlands
  • Research Site
    Amsterdam, 1091 AC, Netherlands
  • Research Site
    Amsterdam, 1105 AZ, Netherlands
  • Research Site
    Gouda, 2803 HH, Netherlands
  • Research Site
    Groningen, 9713 GZ, Netherlands
  • Research Site
    Hoorn, 1625 HV, Netherlands
  • Research Site
    Tilburg, 5022 GC, Netherlands
  • Research Site
    Utrecht, 3584 CX, Netherlands
  • Research Site
    Christchurch, 8011, New Zealand
  • Research Site
    Oslo, 0373, Norway
  • Research Site
    Johannesburg, Gauteng 2193, South Africa
  • Research Site
    Midrand, Gauteng 1685, South Africa
  • Research Site
    Observatory, Western Cape 7925, South Africa
  • Research Site
    Parow, Western Cape 7505, South Africa
  • Research Site
    Cordoba, Andalucía 14004, Spain
  • Research Site
    Zaragoza, Aragón 50009, Spain
  • Research Site
    Reus, Cataluña 43204, Spain
  • Research Site
    Madrid, 28040, Spain
  • Research Site
    Stockholm, 111 35, Sweden
  • Research Site
    Stockholm, 141 86, Sweden
  • Research Site
    Reinach, 4153, Switzerland
  • Research Site
    Coventry, CV2 2DX, United Kingdom
  • Research Site
    London, SE1 7EH, United Kingdom
  • Research Site
    London, W6 8RF, United Kingdom
  • Research Site
    Manchester, M13 9WL, United Kingdom
10

References and documents

Publications

  • Toth PP, Descamps O, Genest J, Sattar N, Preiss D, Dent R, Djedjos C, Wu Y, Geller M, Uhart M, Somaratne R, Wasserman SM; PROFICIO Investigators. Pooled Safety Analysis of Evolocumab in Over 6000 Patients From Double-Blind and Open-Label Extension Studies. Circulation. 2017 May 9;135(19):1819-1831. doi: 10.1161/CIRCULATIONAHA.116.025233. Epub 2017 Mar 1. PubMed 28249876 ↗
  • Kuchimanchi M, Grover A, Emery MG, Somaratne R, Wasserman SM, Gibbs JP, Doshi S. Population pharmacokinetics and exposure-response modeling and simulation for evolocumab in healthy volunteers and patients with hypercholesterolemia. J Pharmacokinet Pharmacodyn. 2018 Jun;45(3):505-522. doi: 10.1007/s10928-018-9592-y. Epub 2018 May 7. PubMed 29736889 ↗
  • Kasichayanula S, Grover A, Emery MG, Gibbs MA, Somaratne R, Wasserman SM, Gibbs JP. Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor. Clin Pharmacokinet. 2018 Jul;57(7):769-779. doi: 10.1007/s40262-017-0620-7. PubMed 29353350 ↗
  • Wasserman SM, Sabatine MS, Koren MJ, Giugliano RP, Legg JC, Emery MG, Doshi S, Liu T, Somaratne R, Gibbs JP. Comparison of LDL-C Reduction Using Different Evolocumab Doses and Intervals: Biological Insights and Treatment Implications. J Cardiovasc Pharmacol Ther. 2018 Sep;23(5):423-432. doi: 10.1177/1074248418774043. Epub 2018 May 16. PubMed 29768954 ↗
  • Raal FJ, Stein EA, Dufour R, Turner T, Civeira F, Burgess L, Langslet G, Scott R, Olsson AG, Sullivan D, Hovingh GK, Cariou B, Gouni-Berthold I, Somaratne R, Bridges I, Scott R, Wasserman SM, Gaudet D; RUTHERFORD-2 Investigators. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet. 2015 Jan 24;385(9965):331-40. doi: 10.1016/S0140-6736(14)61399-4. Epub 2014 Oct 1. PubMed 25282519 ↗
  • Shapiro MD, Minnier J, Tavori H, Kassahun H, Flower A, Somaratne R, Fazio S. Relationship Between Low-Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab. J Am Heart Assoc. 2019 Feb 19;8(4):e010932. doi: 10.1161/JAHA.118.010932. PubMed 30755061 ↗
  • Stroes E, Robinson JG, Raal FJ, Dufour R, Sullivan D, Kassahun H, Ma Y, Wasserman SM, Koren MJ. Consistent LDL-C response with evolocumab among patient subgroups in PROFICIO: A pooled analysis of 3146 patients from phase 3 studies. Clin Cardiol. 2018 Oct;41(10):1328-1335. doi: 10.1002/clc.23049. Epub 2018 Oct 21. PubMed 30120772 ↗
11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2013 to primary completion in Nov 2013, 9 months.

Results were first posted in Dec 2015, 2 years after primary completion. A results delay was requested in May 2014.

Of 122 industry-sponsored phase 3 interventional studies under Hypercholesterolemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 9 months is below that.

Counting every sponsor, half of 125 studies reached it within 18 months; a quarter within 10 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2013
First posted
Jan 9, 2013
StartActual
Feb 7, 2013
Primary completionActual
Nov 27, 2013
CompletionActual
Dec 19, 2013
Results delay requested
May 2, 2014
Results first posted
Dec 22, 2015
Last update
Jun 17, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT01763918
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Jan 9, 2013
Start date
Feb 7, 2013
Primary completion
Nov 27, 2013
Completion
Dec 19, 2013
Results posted
Dec 22, 2015
Last update
Jun 17, 2019

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Evolocumab

Start the discussion